重组人血小板生成素治疗白血病化疗后血小板减少症效果分析

Effect Analysis of Recombinant Human Thrombogenin on Thrombocytopenia After Chemotherapy for Leukemia

目的探讨重组人血小板生成素治疗白血病化疗后血小板减少症效果分析。方法将2019年3月-8月在我院血液科治疗的96例白血病化疗后血小板减少症患者随机分为两组,对照组使用重组人白细胞介素-11治疗,观察组使用重组人血小板生成素治疗,对比两组的治疗前后血小板计数(BPC)变化、BPC恢复所需时间、不良反应情况。结果观察组治疗后7 d、14 d的BPC水平明显高于对照组(P<0.05);观察组BPC<20×10^9/L持续时间、达50×10^9/L所需时间、达100×10^9/L所需时间明显短于对照组(P<0.05);观察组头晕、乏力、发热、肌肉酸痛、皮疹、心动过速等不良反应发生率明显低于对照组(P<0.05)。结论重组人血小板生成素治疗白血病化疗后血小板减少症效果显著,能有效缩短BPC恢复时间,加快BPC恢复速度,且安全性高,具有积极的临床意义。

Objective To investigate the effect of recombinant human thrombogenin in the treatment of thrombocytopenia after chemotherapy for leukemia.Methods In March 2019 to August haematology department in our hospital treatment of 96 patients with leukemia thrombocytopenia after chemotherapy were randomly divided into two groups,control group using recombinant human interleukin-11 treatment,the observation group used human recombinant platelet hormone treatment,compared the two groups before and after treatment the platelet count(BPC)change,time needed for the BPC recovery,adverse reactions.Results The BPC level of the observation group was significantly higher than that of the control group(P<0.05).The duration of BPC<20×10^9/L,the duration of BPC<50×10^9/L,and the duration of BPC<100×10^9/L were significantly shorter in the observation group than in the control group(P<0.05).The incidence of adverse reactions such as dizziness,fatigue,fever,muscle pain,rash and tachycardia in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Recombinant human thrombogenin has a significant effect on treating thrombocytopenia after chemotherapy for leukemia,can effectively shorten the recovery time of BPC,accelerate the recovery speed of BPC,and has a high safety,with positive clinical significance.